NCT01096030View on ClinicalTrials.gov

Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Neoplasms

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)

Trial Locations (4)

119228

Singapore

169610

Singapore

Unknown

Shatin

Hong Kong

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY